Far East Scarlet-Like Fever: A Review of the Epidemiology, Symptomatology, and Role of Superantigenic Toxin: *Yersinia pseudotuberculosis*-Derived Mitogen A

A. Amphlett

Department of Microbiology, Derriford Hospital, Plymouth, United Kingdom

Far East scarlet-like fever (FESLF) is a severe inflammatory disease that occurs sporadically and in outbreaks in Russia and Japan. Far East scarlet-like fever is caused by *Yersinia pseudotuberculosis* infection, an organism that typically causes self-limiting gastroenteritis in Europe. Studies suggest the ability of Far Eastern strains to produce superantigen toxin *Y. pseudotuberculosis*-derived mitogen A is integral to FESLF pathogenesis.

In Europe, human *Y. pseudotuberculosis* infection typically occurs sporadically, in the form of a self-limiting gastroenteritis. In Russia and Japan, outbreaks of *Y. pseudotuberculosis* infection cause severe systemic inflammatory symptoms. This disease variant is called FESLF. Geographical heterogeneity exists between virulence factors produced by European and Far Eastern *Y. pseudotuberculosis* strains, implicating superantigen *Y. pseudotuberculosis*-derived mitogen A (YPMa) in the pathogenesis of FESLF. This article describes the epidemiology and clinical features of FESLF, and it presents the evidence for the role of YPMa in FESLF pathogenesis.

**Keywords.** Far East scarlet-like fever; *Yersinia pseudotuberculosis*; *Yersinia pseudotuberculosis* mitogen A.

*Y. pseudotuberculosis* was first isolated in 1883 [1] from tuberculosis-like lesions in guinea pigs. The organism is 1 of 3 species within the genus pathogenic for humans. *Y. pseudotuberculosis* is a fecal-oral pathogen adept at contaminating chilled food stores due to the organisms ability to proliferate at temperatures as low as 4°C [2].

In Europe, human *Y. pseudotuberculosis* infection typically occurs sporadically, in the form of a self-limiting gastroenteritis. In Russia and Japan, outbreaks of infection cause severe systemic inflammatory symptoms. This disease variant is called Far East scarlet-like fever (FESLF). In Russian and Japan, *Y. pseudotuberculosis* infection is recognized as a national health problem and was added to the national notification system in 1988 [3].

Geographical heterogeneity exists between virulence factors produced by European and Far Eastern *Y. pseudotuberculosis* strains. *Y. pseudotuberculosis*-derived mitogen A (YPMa) is a superantigenic toxin produced almost exclusively by Far Eastern strains [4]. Numerous studies have implicated YPMa as a key player in the pathogenesis of FESLF.

The epidemiological and clinical dichotomy of *Y. pseudotuberculosis* disease has stimulated an exciting body of research. This review summarizes the impact of FESLF across the globe and at the bedside, additionally exploring the role of YPMa in the pathogenesis of this fascinating disease.

**Epidemiology of Far East Scarlet-Like Fever**

*Y. pseudotuberculosis* has a large animal reservoir, causing epizootic disease in European brown hares in Northern Europe, sheep in Australia, and farmed deer in New Zealand. The organism has been isolated in healthy pigs, dogs, cats, cattle, horses, rabbits, and birds. Human transmission arises due to fecal contamination of soil, water, and fresh produce by infected animals [5–10].

Human *Y. pseudotuberculosis* infection has primarily been reported in the Northern hemisphere in Europe, North America, Russia, and Japan, but infection occurs at low incidences on all continents. Disease may arise sporadically or in the form of outbreaks. Most cases are sporadic. Sporadic infection is underreported because stool cultures are not routinely requested in patients presenting with mild clinical features, such as diarrhea. Small outbreaks have been reported in Europe, but large-scale outbreaks have only occurred in Canada, Finland, Russia, and Japan [11, 12]. Far East scarlet-like fever has primarily been observed in Russia and Japan.

In Russia, the first reported epidemic of *Y. pseudotuberculosis* infection occurred in Vladivostok in 1959. Initial disease was characterized by clinical features that led to a misdiagnosis of scarlet fever. A few days later, patients developed different clinical features, and the disease was named FESLF [13].
Between 1959 and 1980, *Y. pseudotuberculosis* infection occurred sporadically and epidemiologically in the Russian Far East only: the Voronezh, Lipetsk, and Stavropol regions; Sverdlovsk, Novosibirsk, and Kemerovo. Of the reported cases, 50%–85% were from outbreaks of FESLF [14].

After 1980, FESLF outbreaks were reported in Central and Western Russia. This change in geographical distribution was facilitated by the following: the intensive socioeconomic development of Eastern and Northern Russia, urbanization, centralization of harvesting, transportation development, and novel fresh produce storage methods. *Yersinia pseudotuberculosis* infection was recognized as a Russian national health problem and included in the national notification system in 1988 [3].

In Russia, between 2000 and 2010, the total mean number of newly registered cases was 6024 per year, and the mean incidence was 4.2 per 100 000 population. Cases differ in their geographical distribution within Russia, with 67.2% of cases being diagnosed in Siberia, 26.6% in the European region, and 7.4% in the Far East [3].

Russia can be subdivided into 4 areas regarding the incidence of *Y. pseudotuberculosis* infection: (1) high-level epidemic territories with incidences greater than 15 per 100 000 (St. Petersburg, Tyumen, Tomsk, Kemerovo, Novosibirsk, Kamchatka, Khakassiya, and Chukotka); (2) middle-level epidemic territories with incidences between 4 and 14 per 100 000 (Arkhangelsk, Murmansk, Leningrad, Magadan, Sakhalin, Altai, and Republic of Altai, Nenetskii, and Khanty-Mansiiskii autonomous districts, Primorsky Krai); (3) low-level epidemic territories with sporadic cases and incidences less than 3.9 per 100 000 (all central Russian provinces, Ural and Volga areas, 5 territories of Siberia, and 4 territories of the Russian Far East); and (4) territories without reported cases (Tyva, Astrakhan, and North Caucasus).

*Yersinia pseudotuberculosis* infection is primarily a disease of children. In Russia, between 2000 and 2010, the incidence of infection in children 14 years and under was 17 per 100 000; the incidence in adults was 1.4 per 100 000, 12.5 times lower. In Russia, human *Y. pseudotuberculosis* infection occurs with equal sex distribution, but in Japan male children are more commonly affected [15].

The incidence of *Y. pseudotuberculosis* disease is seasonal. Incidence increases during the winter, peaks in April–May and ends in June–July. In Russia, this specific intra-annual distribution may be due to the harvest of local vegetables in Northern and Eastern Russia for long-term storage during the winter and the supply of early vegetables from the warm Southern provinces in May–June. In Northern Russian vegetable stores, a study found that 1.6%–2.4% of vegetables were contaminated with *Y. pseudotuberculosis* in December and 16.3%–28.3% in April–June. The supply of infected vegetables to centralized kitchen or restaurant facilities led to outbreaks, whereas distribution via food markets led to sporadic cases [3].

In 1977, an epidemic of *Y. pseudotuberculosis* infection in Japan also gave rise to FESLF. The disease was given a different name, Izumi fever [16]. Between 1977 and 1989, epidemics in Japan were primarily associated with the consumption of contaminated water and contact with infected animals [17]. Between 1989 and 1995, foodborne epidemics occurred almost annually in Japan [15].

**Clinical Features of Yersinia pseudotuberculosis Infection**

In Europe, the symptoms of *Y. pseudotuberculosis* infection are typically gastrointestinal only. The presentation ranges from mild gastroenteritis to pseudappendicular syndrome. Enterocolitis is the typical manifestation in children, whereas terminal ileitis and mesenteric lymphadenitis (the cause of pseudappendicitis) are the typical clinical manifestations in adults; both are self-limiting. Sepsis is uncommon, predominantly occurring in patients with preexisting comorbidities such as the following: diabetes mellitus, liver cirrhosis, or hemochromatosis [18]. During sepsis, bacteria spread preferentially to the liver, spleen, kidney, and lungs forming tuberculosis-like granulomatous abscesses [19]. Postinfective complications are rare but include the following: reactive arthritis, erythema nodosum, iritis, and glomerulonephritis [2]. *Yersinia pseudotuberculosis* has also been implicated in the etiology of Kawasaki disease [20].

In 1959, an epidemic of *Y. pseudotuberculosis* infections in Vladivostok gave rise to severe inflammatory symptoms. The epidemic involved more than 300 people, with 200 of them being hospitalized in a specially organized facility and studied carefully. At disease onset, the majority of patients presented with punctuate rash, hyperemic skin, tonsillitis, pale nasolabial triangle, submandibular lymphadenopathy, and hyperemic tongue. These symptoms led to an initial erroneous diagnosis of scarlet fever. After a few days, the symptoms subsided and new features emerged causing the disease to be named FESLF [13].

Based on the clinical observations of 570 patients Zalmover [21] identified 6 stages of FESLF. The first stage is the Incubation Period, which is asymptomatic and lasts 7–10 days. The second stage is Initial Onset, in which pyrexia, rigors, and more generalized symptoms (such as headache, myalgia, arthralgia, weakness, and appetite loss) occur. Hyperemia of the face and neck, pale nasolabial triangle, hyperemia of the conjunctiva, and swelling of the scleral vessels, coryza, and abdominal pain may also occur at this stage. The third stage is the Accrual Stage. It most commonly occurs 3 days after disease onset. Generalized symptoms, abdominal pain, and arthralgia increase during this stage, and pyrexia is maximal. The scarlet fever-like rash characterizes this stage. The rash has variable presentations being punctuate (rubella or measles-like) or confluent (erythematous-like). Gastrointestinal manifestations are variable, usually manifesting as follows: acute gastritis, gastroenteritis, mesenteric adenitis, or terminal ileitis. Some patients also experience acute cholecystitis. Abdominal pain in the lower right quadrant may mimic appendicitis, and caused up to 40%

[2 • OFID • Amphlett](https://academic.oup.com/ofid/article-abstract/3/1/ofv202/2460569)
of FESLF patients to receive appendectomies in the 1960s. Approximately half of patients develop hepatic lesions exhibiting the features of acute parenchymatous hepatitis. However, morphological liver changes do not persist after symptoms subside. The central nervous system is also commonly affected during the accrual stage: ie, weakness, hypotonia, headache, photophobia, vomiting, and insomnia. Meningism was observed in some patients. Cardiovascular symptoms are uncommon but include syncope, muffled heart sounds, and arrhythmia.

The fourth stage is Remission. This usually occurs 6 days after disease onset. During this stage, there is a decrease in the severity of most symptoms, most notably pyrexia, with persistence of rash and increased jaundice. The fifth stage is Recurrence with Exacerbation. This typically occurs 8 days after disease onset. During this stage, there is an increase in symptom severity, with the exception of pyrexia, and desquamation occurs and jaundice is maximal. The sixth stage is Convalescence. The disease course commonly lasts for 12 days, after which there is gradual resolution of all symptoms including rash, desquamation, and jaundice (Table 1).

Based on the frequency and combination of symptoms Zalmover [21] proposed 5 forms of FESLF, listed in order of decreasing frequency: scarlet fever-like, abdominal, icteric, arthralgic, and generalized. In accordance with this classification, common initial misdiagnoses of FESLF are as follows: scarlet fever, gastroenteritis, appendicitis, viral hepatitis, polyarthritis, tonsillitis, and upper respiratory tract infection.

Serotyping of Yersinia pseudotuberculosis
Serotyping is a common Y pseudotuberculosis typing method, dividing Y pseudotuberculosis into 15 O-serotypes (O:1–O:15) and 10 subtypes (O:1a–O:1c, O2a–O2c, O4a–O4b, and O5a–O5b) based on variability in lipopolysaccharide O-antigen profiles. Most European Y pseudotuberculosis isolates are of serotypes O:1–O:3, whereas serotypes O:4–O:15 are primarily found in Asia. All Y pseudotuberculosis strains are considered potentially pathogenic, but only Y pseudotuberculosis serotypes O:1–O:6 and O:15 have been clinically isolated. The most common clinical serotypes are O:1a, O:1b, and O:3 in Europe and O:4b and O:5b in the Far East. Serotypes O:7–O:14 have only been isolated from environmental and animal sources in Asia (Table 2) [4, 22].

Genotyping of Yersinia pseudotuberculosis
Fukushima et al [4] divided Y pseudotuberculosis into 6 genetic groups (G1–G6) based on the presence of 3 key virulence factors: the Y pseudotuberculosis virulence plasmid (pYV), the high pathogenicity island (HPI), and the subtype of Y pseudotuberculosis-derived mitogen produced (YPMa/YPMb/YPMc) (Table 3).

Table 1. Clinical Features of Far East Scarlet-Like Fever

| System                      | Occurring at Disease Onset and Persisting With Variable Severity Throughout the Disease | Occurring During the Accrual Stage | Occurring Later in the Disease Course |
|-----------------------------|--------------------------------------------------------------------------------------------|-----------------------------------|---------------------------------------|
| General                     | Pyrexia, rigors, headache, appetite loss                                                    |                                   |                                       |
| Neurological                | Hypertonia, photophobia, insomnia, meningism*                                              |                                   |                                       |
| Respiratory                 | Coryza                                                                                     |                                   |                                       |
| Cardiovascular              | Syncope*, muffled heart sounds*, arrhythmia*                                               |                                   |                                       |
| Gastrointestinal            | Abdominal pain                                                                             | Nausea, vomiting, diarrhea        |                                       |
| Hepatobiliary               |                                              |                                   |                                       |
| Musculoskeletal             | Myalgia, athalgia                                                                         |                                   |                                       |
| Dermocutaneous              | Hyperemia of the face, neck and/or conjuctiva. Pale nasolabial triangle.                   | Punctuate/confluent rash          | Desquamation                          |

* Uncommon clinical feature.

Table 2. Serotyping Scheme and Isolation Source of Yersinia pseudotuberculosis

| O Groups | O Subgroups | Clinically Isolated | Location Isolated |
|----------|-------------|---------------------|-------------------|
| 1        | 1a 1b 1c    | Yes* Yes*           | Europe            |
|          | 2a 2b2c     | Yes                 | Europe and Far East|
| 3        | 4a 4b       | Yes                 | Far East          |
| 5        | 5a 5b       | Yes                 | Europe and Far East|
| 6        | 6           | Yes                 | Europe            |
| 7        | 7           | No                  | Far East          |
| 8        | 8           | No                  | Far East          |
| 9        | 9           | No                  | Far East          |
| 10       | 10          | No                  | Far East          |
| 11       | 11          | No                  | Far East          |
| 12       | 12          | No                  | Far East          |
| 13       | 13          | No                  | Far East          |
| 14       | 14          | No                  | Far East          |
| 15       | 15          | Yes                 | Far East          |

* Most common clinically isolated Y pseudotuberculosis serotypes in Europe.

** Most common clinically isolated Y pseudotuberculosis serotypes in Russia and Japan.
Multilocus Sequence Typing of \textit{Yersinia pseudotuberculosis}

Serotyping and genotyping are products of classic taxonomic criteria, which include pairwise DNA-DNA reassociation and biochemical testing. However, considerable genetic diversity exists within \textit{Yersinia} species. Multilocus sequence typing has been used to further delineate the population genetic structure of \textit{Y pseudotuberculosis}.

Multilocus sequence typing reveals that the “Y \textit{pseudotuberculosis} complex” comprises of 3 distinct populations: the \textit{Yersinia pestis}/\textit{Y pseudotuberculosis} group, \textit{Yersinia similis}, and the Korean group. This distinction has been confirmed by D-raffinose and D-melibiose fermentation and pyrazinamidase activity [23, 24].

\textit{Yersinia similis} expresses \textit{Y pseudotuberculosis}-derived mitogen B and lacks pYV and HPI. Isolates belong to genetic type G4. The strain is thought to be apathogenic in humans and has only been isolated in Japan and Germany from small mammals and the environment. \textit{Yersinia similis} may cause diagnostic problems due to being biochemically indistinct from \textit{Y pseudotuberculosis} by commercial test kits [25].

The Korean group resemble \textit{Y pseudotuberculosis} but are genetically more distinct and may be in the process of becoming a different species. Isolates belong to genetic types G3 and G6, which are considered pathogenic. Korean groups’ strains have been isolated from humans, suggesting clinical relevance [23].

\textit{Yersinia pseudotuberculosis} Virulence Plasmid

The presence of the pYV is requisite for pathogenicity in \textit{Yersinia} species; therefore, the presence or absence of this plasmid divides strains into pathogenic (G1–G3, G5–G6) and non-pathogenic subgroups (G4). Subgroups G2 and G3 comprise the majority of clinical isolates, and subgroups G1, G2, and G6 comprise the minority.

The major virulence factors encoded by pYV are a type III secretion system and effector proteins termed \textit{Yersinia} outer proteins (Yops). The YopE is a GTPase-activating protein, and YopH is a protein tyrosine phosphatase, both of which are antiphagocytic. The YopO/YpkA is a serine threonine kinase. The YopM can transit to the host cell nucleus. The YopJ/P inhibits the production of proinflammatory cytokine tumor necrosis factor-α (TNF-α) and induces macrophage apoptosis. The YopT is a cytotoxin that causes actin filament disruption. All Yops have additionally been shown to disrupt intracellular signaling or result in cytoskeletal changes that interfere with phagocytosis [26]. The pYV also encodes proteins involved in the control and translocation of the effector Yops to the target cell: YopN, YopB, YopD, TyeA, lcrG, and lcrV. Pathogenic \textit{Yersinia} species preferentially target the cells of the innate immune system (neutrophils, macrophages, and dendritic cells) for injection of Yops, attenuating the innate immune response [27].

High Pathogenicity Island

The most common clinical genotype in Europe is G2, a strain that possesses pYV and the HPI. The HPI is a 36-kb chromosomal DNA fragment that carries the biosynthetic gene cluster for yersiniabactin, a molecule involved in siderophore-mediated iron acquisition [28]. Iron uptake is a prerequisite for successful bacterial growth and dissemination. The presence of HPI and yersiniabactin production has been shown to increase virulence [29].

Yersiniabactin is produced by almost all European strains causative of non-FESLF disease (serotypes: O:1a, O:1b, O:2b, and O:3) and is absent from almost all Far Eastern strains causative of FESLF (O:1b, O:2, O:3, O:4, and O:5).

\textit{Yersinia pseudotuberculosis}-Derived Mitogen A

The most common clinical genotype in Russia and Japan is G3, a strain possessing pYV and producing the superantigenic toxin YPMa. The YPMa is produced by all Far East clinical strains.
causative of FESLF and is absent from almost all European strains causative of non-FESLF disease. The HPI is absent from most Far Eastern strains, which may represent divergent phylogenetic origin rather than secondary loss [4].

Superantigenic activity in Y pseudotuberculosis was first reported in 1993 [30, 31]. The identified toxin was named YPM after it was observed that the toxin had a mitogenic effect on T-cell populations. The YPM is the only superantigenic toxin identified in Gram-negative bacteria. Superantigens are also produced by Staphylococcus aureus, Staphylococcus pyogenes, and some retroviruses. Three YPM variants have been detected: YPMa, YPmb, and YPMc, encoded by chromosomal genes of the same name (ypmA, ypmB, and ypmC) [32].

Patients with severe FESLF have higher titers of anti-YPMa, immunoglobulin G, and YPMa-responsive T cells [30]. In the intravenous mouse model of infection, a strain in which ypmA had been inactivated caused prolonged mean time to death in comparison to the wild type. However, no significant difference was observed between the ΔypmA mutant and the wild type via the intragastric route [33].

The term “superantigen” refers to YPMa possessing 3 additional properties, in addition to those of a conventional antigen: (1) YPMa is able to bind directly to major histocompatibility complex (MHC) class II molecules on antigen presenting cells [34]; (2) YPMa has a specificity for a set of Vβ elements, the variable region on the beta chain of a T-cell receptor, and this interaction is independent of antigen specificity [35]; and (3) YPMa is able to activate T cells, which are CD4+ or CD8+, including T cells from donors with different MHC class II alleles [36, 37].

The pathological implication of these properties are that YPMa is able to bind directly to MHC class II molecules, activating T cells as rapidly as conventional antigens activate innate immune cells [34]. In addition, YPMa is able to interact with a subset of T cells containing Vβ elements: Vβ3, Vβ9, Vβ13.1, and Vβ13.2, activating between 5% and 20% of the entire T-cell population [38].

The resultant effect is that a large proportion of active T cells produce TNF-α [39], interferon (IFN)-γ [40], and interleukin (IL)-2 [41]. These cytokines stimulate macrophages, natural killer cells, vascular endothelial cells, and fibroblasts to produce a variety of inflammatory cytokines and chemokines such as the following: IL-1 [42], IL-6, TNF-α [43], IL-12 [44], IL-8 [45], macrophage inflammatory protein (MIP)-1α, MIP-2α [46], monocyte chemoattractant protein (MCP)-1 [47], and MCP-2 [48]. These mediators promote pyrogen and acute reactive protein release and increase vascular permeability.

Diseases caused by superantigenic toxin-producing bacteria share clinical features such as the following: high-grade fever, conjunctival inflammation, pharyngeal inflammation, and latent development of an erythematous skin rash followed by desquamation in the convalescent phase [49, 50]. Superantigens have been shown to enhance susceptibility to lipopolysaccharide-induced shock [51].

**DISCUSSION**

The differing clinical manifestation of Y pseudotuberculosis infection in Europe, compared with that of Russia and Japan, has been recognized since 1959 [13], but only within the last 10 years have FESLF-associated genomic elements been identified. The superantigenic properties of YPMa were first recognized in 1993 [30, 31], and a strong association was established between the presence of gene ypmA and strains causative of FESLF in 2001 [4].

The mechanism by which YPMa causes FESLF is likely to be multifactorial. A study that injected purified YPMa subcutaneously into mice found that toxic shock did not occur when monoclonal antibodies were used against TNF-γ, IFN-γ, or CD4, implicating these cytokines and T-cell subtype in the pathogenesis of YPMa-induced toxic shock syndrome [52]. In addition, a variation in susceptibility of mice to Yersinia infection has been reported due to variable IFN-γ production [53]. Superantigens have been shown to potentiate the toxicity of endotoxins, such as lipopolysaccharide, and this synergistic action may additionally contribute to morbidity [54].

The majority of Far East Y pseudotuberculosis strains produce YPMa, but not all cases of Y pseudotuberculosis infection cause FESLF, suggesting interplay between the superantigen and other virulence factors. Genome sequencing of a FESLF causing Y pseudotuberculosis strain has implicated additional virulence factors that may be involved in the pathogenesis of the disease [55]. These genomic elements include the following: plasmid VM82, Yersinia adhesion pathogenicity island (YAPI), which encodes and type IV pilus [56], and the genes ace64 and helic contained within a horizontally acquired pathogenicity island. It would be useful to additionally inactivate these genes in a ΔypmA mutant and use the resultant strain in the mouse model of infection. Survival data could be analyzed to discern whether any of these genomic elements potentiate the pathogenicity of YPMa.

Patient factors may also play a role in whether YPMa-producing strains give rise to FESLF. The FESLF typically affects children <14 years old [3], and in Japan male children are 1.5 times more commonly affected than females [15]. An exploration of patient factors from a public health and immunological perspective would be useful to further understand the relationship between YPMa-producing strains and FESLF.

**CONCLUSIONS**

Human Y pseudotuberculosis infection occurs sporadically in Europe, but in Russian and Japan epidemiological outbreaks and more severe clinical manifestations significantly contribute to national morbidity. An explanation for this dichotomy is the geographical heterogeneity of virulence factors produced.
Emerging evidence suggests that YPMA is likely to be a key player in the pathogenesis of FESLF. However, the nature of this association is complicated by interactions with other virulence factors and host immunology.

Acknowledgments

Potential conflict of interest. All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

References

1. Malassez L, Vignal W. On microorganisms of zoological tuberculoises [Sur le microorganisme de la tuberculose zoologique]. Arch Physiol Norm Pathol 1884; 3: 71–80.
2. Bottone EJ, Bercovier H, Mollaret HH. Genus XLI. Yersinia. In: Garrity GM, Brenner DJ, Krieg NR, Staley JT, ed. Bergey’s Manual of Systematic Bacteriology, 2nd ed. Springer: New York; 2005: pp 836–48.
3. Tsenova GV, Chesnokova MV, Timofeevich KV, et al. Pseudotuberculosis in the Russian Federation. Adv Exp Med Biol 2012; 954:63–8.
4. Fukushima H, Matsuda Y, Seki R. Geographical heterogeneity between Far East and Western countries in prevalence of the virulence plasmid, the superantigen Yersinia pseudotuberculosis derived mitogen and the high-pathogenicity island among Yersinia pseudotuberculosis strains. J Clin Microbiol 2001; 39:3541–7.
5. Wuthie KH, Alexesi S, Kwapi S. Yersinia in the European brown hare of Northern Germany. Contrib Microbiol Immunol 1995; 13:51–4.
6. Sree K, Skillibeck NW. Epidemiology of Yersinia pseudotuberculosis and Y. enterocolitica infections in sheep in New Zealand. J Clin Microbiol 1992; 30:712–7.
7. Wilson PR. Advances in health and welfare of farmed in New Zealand. N Z Vet J 2002; 50(Suppl 3):105–9.
8. Norto JP, Niskanen T, Hallanvuo S, et al. A widespread outbreak of Yersinia pseudotuberculosis O:3 infection from iceberg lettuce. J Infect Dis 2004; 189:766–74.
9. Rimhanen-Finne R, Niskanen T, Hallanvuo S, et al. Yersinia pseudotuberculosis causing a large outbreak associated with carrots in Finland, 2006. Epidemiol Infect 2009; 137:342–7.
10. Fukushima H, Gomyoda M, Tsubokura M, Aleksić A, et al. Pathophysiology of Yersinia pseudotuberculosis in mice. Infect Immun 2000; 68:2553–9.
11. Jardetzky TS, Brown JS, Gerbini GC, et al. Three-dimensional structure of a human class II histocompatibility protein complexdocile with superantigen. Nature 1994; 368:711–8.
12. Kappler J, Kotzin B, Herron L, et al. Y beta-specific stimulation of human T cells by staphylococcal toxins. Science 1989; 244:811–3.
13. DellaPina P, Pecocc J, Kappler J, et al. Superantigens interact with MHC class II molecules outside of the antigen groove. Cell 1990; 62:1115–21.
14. Scholl PR, Diez A, Karr R, et al. Effect of isotypes and allelic polymorphism on the binding of staphylococcal exotoxins to MHC class II molecules. J Immunol 1990; 144:226–30.
15. Zippelius A, Pittet MJ, Batard P, et al. Thymic selection generates a large T cell pool recognizing a self-peptide in humans. J Exp Med 2002; 195; 485–94.
16. Fast DJ, Schlevert PM, Nelson RD. Toxic shock syndrome-associated staphylococcal and streptococcal pyrogenic toxins are potent inducers of tumor necrosis factor production. Infect Immun 1989; 57:291–4.
17. Jupin G, Anderson S, Damas C, et al. Toxic shock syndrome toxin 1 as an inducer of human tumor necrosis factors and gamma interferon. J Exp Med 1988; 167:752–61.
18. Uchiyama T, Kamagata Y, Waku M, et al. Study of the biological activities of toxic shock syndrome toxin 1: Proliferative response and interleukin 2 production by T cells stimulated with the toxin. Microbiol Immunol 1986; 30:469–83.
19. Ikejima T, Inadze CA, Gill DM, Wolff SM. Induction of human interleukin 1 by a product of Staphylococcus aureus associated with toxic shock syndrome. J Clin Invest 1984; 73:1312–20.
20. Mietthke T, Wahl C, Regle D, et al. Superantigen mediated shock: a cytokine release syndrome. Immunobiology 1993; 189:270–84.
21. Leung DY, Gately M, Troumba A, et al. Bacterial superantigens induce T cell expression of the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen, via stimulation of interleukin 12 production. J Exp Med 1995; 181:747–53.
22. König B, Moller M, Prevost G, et al. Activation of human effector cells by different bacterial toxins (leukocidin, alveolysin, and erythrogenic toxin A): generation of interleukin-8. Infect Immun 1994; 62:4831–7.
23. Tessler PA, Nacache PH, Diener KR, et al. Induction of acute inflammation in vivo by staphylococcal superantigens. II. Critical role for chemokines, ICAM-1, and TNF-alpha. J Immunol 1998; 161:1204–11.
24. Newman I, Wilkinson PC. The bacterial superantigen Staphylococcus enterotoxin B stimulates lymphocyte locomotor capacity during culture in vitro. Immunology 1996; 87:428–33.
25. Neumann B, Emmanuilidis K, Stadler M, Holzmann B. Distinct functions of interferon-gamma for chemokine expression in models of acute lung inflammation. Immunology 1998; 93:12–21.
26. Todd J, Fishbath M, Krapel F, Welch T. Toxic shock syndrome associated with phage-group I Staphylococci. Lancet 1978; 2:1116–8.
27. Cone LA, Woodard DR, Schlevert PM, Tomory GS. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med 1987; 317:146–9.
28. Bobach GA, Fast DJ, Nelson RD, Schlevert PM. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses. Crit Rev Microbiol 1990; 17:251–72.
52. Miyoshi-Akiyama T, Fujimaki W, Yan XI, et al. Identification of murine T cells reactive with the bacterial superantigen *Yersinia pseudotuberculosis*-derived mitogen (YPM) and factors involved in YPM-induced toxicity in mice. Microbiol Immunol 1997; 41:345–52.

53. Autenrieth IB, Beer M, Bohn E, et al. Immune responses to *Yersinia enterocolitica* in susceptible BALB/c and resistant C57BL/6 mice: an essential role for gamma interferon. Infect Immun 1994; 62:2590–9.

54. Blank C, Luz A, Bendigs S, et al. Superantigen and endotoxin synergize in the induction of lethal shock. Eur J Immunol 1997; 27:825–33.

55. Eppinger M, Rosovitz MJ, Fricke WF, et al. The complete genome sequence of *Yersinia pseudotuberculosis* IP31758, the causative agent of Far East scarlet-like fever. PLoS Genet 2007; 3:e142.

56. Collyn F, Léty MA, Nair S, et al. *Yersinia pseudotuberculosis* harbors a type IV pilus gene cluster that contributes to pathogenicity. Infect Immun 2002; 70:6196–205.